April 29, 2013 One-quarter of women who should take hormone-blocking therapies as partial of their breast cancer diagnosis possibly do not start or do not finish a 5-year course, according to a new study. Five years of daily tamoxifen or aromatase inhibitors—two forms of endocrine therapy that are taken as a pill—is endorsed for many [...]
↧